BG heads into its July 29 Q2 earnings report with a rare divergence: options traders turned notably more defensive on the final trading day before the event, even as the analyst community has spent months lifting targets and sticking with bullish ratings.
The options signal is the sharpest edge in the setup. The put/call ratio jumped to 0.35 on July 24 — more than two standard deviations above its 20-day average of 0.31, the highest defensive skew in at least several weeks. That single-day move stands in contrast to the stock's recent trajectory: BG has gained nearly 10% over the past month to close at $121.53, making the sudden tilt toward puts feel more like earnings insurance than a directional bet. Elsewhere, the borrow market is entirely relaxed — availability has widened to over 1,300%, meaning shares to lend outnumber shares already borrowed by more than thirteen to one. Cost to borrow runs below 0.5%, down roughly 8% on the week. Short interest, at 3.4% of the free float, has drifted down almost 10% over the past month, suggesting existing bears have been quietly reducing exposure into the stock's run-up.
Analysts have been a one-way story for most of this year. Since February, Barclays, JP Morgan, Morgan Stanley, UBS, and BMO Capital all lifted targets, with the consensus mean now at $141 — roughly 16% above the current price. The bull case centres on biofuel policy clarity driving crush margin improvement in the second half of the year, strength in global grains merchandising, and Bunge's expectation that full-year results will exceed earlier guidance. Bears counter that the Agribusiness segment has faced sharp EBIT declines in processing, that Refined & Specialty Oils and Milling have both lagged year-on-year, and that merchandising results for the year are projected to slip despite the Viterra integration. Note that the Benzinga bull/bear framing dates to October 2025 — the broad directional tension still applies, but specific segment details may have evolved since.
One institutional detail worth flagging: Capital Research and Management added over 3.6 million shares in the most recent reported period, pushing its stake to nearly 10.7% of shares outstanding — making it the third-largest disclosed holder behind Glencore (16.9%) and Canada Pension Plan (13.5%). That kind of deliberate accumulation by a long-only fundamental manager sits awkwardly alongside the late options defensiveness and the modest but steady short position.
The July 29 print will test whether Bunge's crush margin recovery and Viterra integration benefits are materialising fast enough to justify a stock that has already re-rated nearly 10% in a month — and whether the sudden pre-earnings put demand reflects genuine uncertainty or simply routine hedging against a rally that has moved faster than the underlying fundamentals.
See the live data behind this article on ORTEX.
Open BG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
